Vir Biotechnology (VIR)
(Real Time Quote from BATS)
$5.15 USD
-0.03 (-0.58%)
Updated Sep 19, 2025 02:00 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIR 5.15 -0.03(-0.58%)
Will VIR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Other News for VIR
VIR Crossed Above 20 Day Moving Average on September 18
20 Day Moving Average Resistance appears for VIR after 1.23% move
Is VIR poised for a decline? 20 Day Moving Average Resistance shows up after rising 1.46%
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Is VIR preparing to trend lower? Fell Below 20 Day Moving Average shows up after sliding 4.2%